Bayard Powell to Arsenicals
This is a "connection" page, showing publications Bayard Powell has written about Arsenicals.
Connection Strength
1.005
-
Powell BL. Arsenic trioxide in acute promyelocytic leukemia: potion not poison. Expert Rev Anticancer Ther. 2011 Sep; 11(9):1317-9.
Score: 0.393
-
Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11; 116(19):3751-7.
Score: 0.365
-
Poiré X, Moser BK, Gallagher RE, Laumann K, Bloomfield CD, Powell BL, Koval G, Gulati K, Holowka N, Larson RA, Tallman MS, Appelbaum FR, Sher D, Willman C, Paietta E, Stock W. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma. 2014 Jul; 55(7):1523-32.
Score: 0.116
-
Levy M, Wofford MM, Powell BL, McLean TW. Hyperleukocytosis from arsenic trioxide. Pediatr Blood Cancer. 2008 Jun; 50(6):1265-7.
Score: 0.078
-
Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FR. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol. 2014 May; 165(4):497-503.
Score: 0.029
-
Tallman M, Douer D, Gore S, Powell BL, Ravandi F, Rowe J, Ranganathan A, Sanz MA. Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy. Clin Lymphoma Myeloma Leuk. 2010 Oct; 10 Suppl 3:S122-6.
Score: 0.023